Hybridization capture method and composition

The method of hybridization capture at lower temperatures with a 'melting' step and optimized buffer compositions addresses the inefficiencies of current methods, achieving faster and more specific target sequence capture.

JP7850673B2Active Publication Date: 2026-04-23INTEGRATED DNA TECHNOLOGIES INC +3
View PDF 7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
INTEGRATED DNA TECHNOLOGIES INC
Filing Date
2021-03-25
Publication Date
2026-04-23

AI Technical Summary

Technical Problem

Current hybridization capture methods face challenges such as long workflow times, high complexity, and non-uniform capture of target sequences, particularly in biologically complex samples, with issues like off-target binding and sequence bias.

Method used

A method involving hybridization at lower temperatures, followed by selective immobilization and a 'melting' step to dissociate off-target sequences, combined with optimized buffer compositions to enhance specificity and efficiency.

Benefits of technology

This approach significantly reduces hybridization time, improves capture specificity, and enhances uniformity and yield of target sequences, making the process more efficient and amenable to automation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007850673000012
    Figure 0007850673000012
  • Figure 0007850673000013
    Figure 0007850673000013
  • Figure 0007850673000014
    Figure 0007850673000014
Patent Text Reader

Abstract

Described herein are methods and compositions for improved hybridization capture to enrich target nucleic acid sequences from a population of nucleic acids. In one aspect, the methods and compositions are useful in next-generation sequencing (NGS) applications. The methods and compositions include combining a capture probe and a target nucleic acid in solution and hybridizing the target nucleic acid to the capture probe under conditions that promote efficient hybridization. After hybridization, the probe / target complex is immobilized on a capture material while simultaneously incubating at an optimal hybridization temperature. The incubation denatures undesired nucleic acids from the capture probe and further enriches the target nucleic acid.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 000,140, ​​filed on 26 March 2020, the contents of which are incorporated herein by reference in their entirety.

[0002] This specification describes methods and compositions for improved hybridization capture to enrich target nucleic acid sequences from a population of nucleic acids. In one embodiment, these methods and compositions are useful in next-generation sequencing (NGS) applications. [Background technology]

[0003] In DNA and RNA analysis, it is often efficient to examine a selected population of target sequences within a composite sample, such as a genome, multiple genome, cfDNA, ctDNA, RNA-derived sample, or FFPE sample, to detect multiple variations. The selected sequences are then targeted for isolation ("target capture") for downstream workflows, such as amplification, point-of-care detection, sequencing, or chemical / biological growth.

[0004] Two approaches to target capture are hybridization target capture (hyb-capture) or multiplex PCR (amplicon enrichment).

[0005] Multiplex PCR technology is fast, highly sensitive, and typically offers a user-friendly, simple, and efficient workflow. However, the number of target sequences that can be examined (captured) simultaneously is limited to at most a few thousand PCR-primer pairs. Furthermore, there are challenges in the uninterrupted presentation of continuous long chains (several kilobases), capture uniformity, and quantitative measurement. Some of the challenges with multiplex PCR are generally addressed by existing hybridization capture techniques.

[0006] Other methods, such as molecular inversion probes (MIPs) or padlock probes, face similar challenges to those faced by methods based on amplicon enrichment.

[0007] There are various commercially available hybridization-capture (hyb-capture) methods. Regarding hyb-capture, nucleic acids are not limited to dsDNA, dsRNA, or hybrid DNA-RNA complexes. Capture of any nucleic acid species is possible at the double-stranded nucleic acid melting temperature (T). m It relies on a similar approach to capture a subset of target sequences from a composite mixture, based on hybridization under conditions predicted by ). The hyb-capture method follows the following general workflow: (A) A composite sample, such as a library of genomic DNA (target nucleic acid), is incubated with a pool of thousands or hundreds of thousands of targeting probe (or "bait") sequences in a specially formulated hybrid capture solution. (B) The targeting probe is hybridized to the target sequence in the form of an amplified template. The hybridized complex is then often captured by another substrate. Capture often requires additional incubation, often combined with mixing. (C) The capture material from step B is vigorously washed in multiple steps to remove off-target nucleic acids, and the resulting concentrated capture material is prepared for sequencing. If the capture material from step B is extended to form an amplified template suitable for sequencing, the washing step in step C is not necessary. However, extending the target material presents the challenge of reducing complexity.

[0008] A typical hybridization capture method involves determining the expected probe-target melting temperature (T m The probe and target are brought into contact under conditions that are considered "specific" regarding ). m This is usually determined empirically by heating (melting) double-stranded nucleic acids under specific conditions. Such direct experimental observations can be applied directly or under hybridization capture conditions. m It is used to calculate / predict T. mThis does not explain the complex kinetics and probabilities in double-stranded binding and formation in biologically complex samples. The probe and target must first bind by accidental nucleation. Regarding the event of productive nucleation, the probe-target pair must "sample" each other. See Yin and Zhao, Acc. Chem. Res. 44(11):1172~1181 (2011). The duration of such binding and "sampling" depends on the hybridization conditions and the degree of complementarity. Such binding / sampling events occur continuously and iteratively until the system reaches the lowest energy state (thermodynamic equilibrium). It should be noted that off-target binding with an appropriate level of complementarity can confine the probe-target pair for a long time, preventing each from hybridizing with a perfectly complementary target nucleic acid. Double-stranded nucleic acids of such mispaired pairs can survive the entire hybridization-capture process. Incubation at high temperatures for extended periods maximizes preferred target / probe hybridization and reduces off-target pairs. Hybridization capture is typically used to minimize the formation of off-target hybridizations, resulting in predicted double-stranded T13s. m Immediately below, or its T m This is performed. Off-target double-stranded proteins undergo less base pairing and therefore have a higher T than the intended target / probe complex. mLow incubation periods are expected, and shorter incubation periods are anticipated. Current approaches overlook the fact that such energy differences are only reflected in the molecular population when the system is in thermodynamic equilibrium, which may take a long time to achieve. Empirical data using oligonucleotide systems on microarrays have shown that such equilibrium is approached (but not reached) after 40 hours at high temperatures with continuous and very vigorous mixing. Wang et al., RNA 13(1):151~159 (2007). Hybridization of longer, more complex probe-target mixtures is likely to take longer to approach equilibrium, even if similar temperature stringency and rigorous mixing can be achieved on an open platform. Consequently, hybridization-capture requires long incubation periods to approach homogeneity and yield, even under ideal probe design and hybridization conditions.

[0009] Hybridization-capture can achieve extremely high complexity (hundreds of thousands of probe sequences simultaneously in a single capture reaction) and provide continuous and quantitative coverage of long genome extensions, but its workflow is long and cumbersome. A typical workflow involves many time-constrained manual steps performed by experienced operators to obtain reproducible and consistent results. Furthermore, coverage uniformity and specificity are challenges, which are typically tuned by stringency in probe design, hybridization solution formulation, hybridization time, and post-hybridization-capture washing steps. The assay still commonly suffers from under- or over-sampling of GC or AT-rich regions.

[0010] There is a need for methods and compositions to overcome existing problems of the current technology, reduce the complexity of workflows, shorten the hybridization-capture time, increase the capture complex target region, and improve the specific and uniform capture of target sequences or regions.

Summary of the Invention

[0011] Described herein are methods and compositions for improved hybridization capture for enriching target nucleic acid sequences from a population of nucleic acids. The method includes combining a probe set complementary to a population of nucleic acids in solution; hybridizing or binding the complementary probe set to the target nucleic acid; selectively immobilizing the probe / target nucleic acid complex; exposing the selectively immobilized probe / target nucleic acid complex to a lower temperature to melt unwanted non-target substances; and washing the complex to remove unbound non-target substances, thereby enriching the target nucleic acid. m The method includes exposing the complex to a lower temperature to melt unwanted non-target substances and washing the complex to remove unbound non-target substances, thereby enriching the target nucleic acid.

[0012] One embodiment described herein relates to the ability to shorten the hybridization time of hybridization capture. One aspect described herein reduces the complexity of the hybridization capture workflow. Another aspect described herein improves the capture specificity of the composite target region. Another aspect described herein improves the specific capture of target nucleic acid sequences or regions while minimizing sequence bias.

[0013] Another embodiment described herein provides an improved hybridization capture composition. Another aspect described herein provides an improved hybridization capture buffer.

[0014] Another embodiment described herein is a method for hybridization capture. This hybridization capture method is a Hyb-capture-thaw workflow. In the first step, a probe panel is brought into contact with a nucleic acid sample under conditions that promote hybridization. Optionally, the probe panel may include a capture portion, for example, biotinylation, but is not limited to this. The biotinylation probe is complementary to the target nucleic acid or the nucleic acid to be enriched. In the first step, the goal is to increase the yield of hybridization capture. Specificity of nucleic acid capture is secondary to yield. In the second step, the biotinylation probe is immobilized on streptavidin beads. Probes containing and not containing the hybridized target are immobilized. In the third step, thawing is performed to dissociate all nonspecific hybridization interactions. While not bound by theory, it is also expected that after thawing, rehybridization of the captured probe and target sequence occurs, further improving both yield and specificity. In the fourth step, a washing step is performed to further remove unhybridized and weakly hybridized non-target nucleic acids.

[0015] Another embodiment described herein is an improved composition for hybridization capture. In one embodiment, a hybridization capture buffer is provided that improves hybridization capture efficiency. In another embodiment, T m Modified reagents may be added. In another embodiment, T to the double-stranded target GC base content. m The capture can be improved by adding additives that reduce dependency.

[0016] Another embodiment described herein is a method for hybridization capture. In one step, hybridization at low stringency is provided. In another step, capture (immobilization) is carried out at a temperature sufficient to facilitate immobilization. In another step, melting is carried out at a high temperature to reduce off-target hybridization. In another step, washing is carried out to reduce off-target hybridization, and if necessary, this washing step may be without high-temperature washing.

[0017] One embodiment described herein comprises the steps of (a) preparing a sample of nucleic acid molecules comprising a plurality of target nucleic acid sequences and a plurality of off-target nucleic acid sequences; (b) hybridizing the sample to a panel of nucleic acid probes complementary to the plurality of target nucleic acid sequences under hybridization conditions to generate a probe / target complex; (c) selectively immobilizing the probe / target complex to form an immobilized probe / target complex; and (d) agglutinating the immobilized probe / target complex at a temperature below T, for a time sufficient to dissociate the off-target nucleic acid sequences. mA method for enriching a population of nucleic acid target sequences in a sample, comprising the steps of: (a) heating; and (b) washing the immobilized probe / target complex to remove non-hybridized nucleic acid sequences and off-target nucleic acid sequences from the hybridized multiple target nucleic acid sequences, thereby enriching the multiple target nucleic acid sequences in the sample. In one embodiment, the panel of nucleic acid probes complementary to the multiple target nucleic acid sequences further comprises a capture portion. In another embodiment, the capture portion is biotin. In another embodiment, the hybridization conditions are: (a) a salt selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) a chelating agent selected from one or more of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[Tris(hydroxymethyl) A buffer selected from one or more of the following: tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate);(d) A surfactant selected from one or more of sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyl ethanol (NP-40), or cetrimonium bromide (CTAB); or (e) An additive selected from one or more of glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400 - 1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA), wherein the hybridization buffer contains one or more of them. In another embodiment, the hybridization buffer contains formamide. In another embodiment, the hybridization buffer does not contain formamide.;

[0018] In one embodiment, the hybridization conditions include an incubation time in the range of 10 minutes to 48 hours. In one aspect, the hybridization conditions include an incubation time in the range of 2 hours to overnight. In another aspect, compared to an overnight incubation time, an incubation time of 2 hours provides equivalent specificity and equivalent yield. In another aspect, the hybridization conditions include an incubation temperature in the range of about 55°C to about 75°C. In another aspect, the hybridization conditions include an incubation temperature in the range of about 60°C to about 70°C. In another aspect, the hybridization conditions include an incubation time of 2 hours and an incubation temperature of about 65°C.

[0019] In another embodiment, the probe / target complex is selectively immobilized using streptavidin beads. In one embodiment, the probe / target complex is selectively immobilized under conditions including an incubation time in the range of about 10 minutes to about 48 hours. In another embodiment, the probe / target complex is selectively immobilized under conditions including an incubation temperature in the range of about 20°C to about 40°C. In yet another embodiment, the probe / target complex is selectively immobilized under conditions including an incubation time of about 30 minutes and an incubation temperature of room temperature. In another embodiment, the step of heating the immobilized probe / target complex is: (a) a salt selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) a chelating agent selected from one or more of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[Tris( A buffer selected from one or more of the following: [Hydroxymethyl)methyl]glycine (Tricine); [Tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenate (Cacodylate);(d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) a fusion buffer comprising one or more additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA). ;

[0020] In another embodiment, the step of heating the immobilized probe / target complex includes an incubation time ranging from about 5 minutes to about 1 hour. In one embodiment, the step of heating the immobilized probe / target complex includes an incubation temperature ranging from about 50°C to about 70°C. In another embodiment, the step of heating the immobilized probe / target complex includes an incubation time of about 20 minutes and an incubation temperature of about 55°C. In another embodiment, the step of washing the immobilized probe / target complex comprises two different washing buffers, each washing buffer independently comprising: (a) a salt selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) a chelating agent selected from one or more of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid A buffer selected from one or more of the following: (Bicine); N-[Tris(hydroxymethyl)methyl]glycine (Tricine); [Tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate);(d) A surfactant selected from one or more of sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyl ethanol (NP-40), or cetrimonium bromide (CTAB); or (e) an additive selected from one or more of glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400 - 1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA), including one or more of them.;

[0021] In another embodiment, the step of washing the immobilized probe / target complex includes an incubation time of about 5 minutes to about 15 minutes and an incubation temperature of about 60°C. In one aspect, this method improves specificity and increases yield compared to conventional methods. In another aspect, the conventional method does not include a heating step before the washing step. In another aspect, this method improves the percentage of on-target compared to conventional methods. In another aspect, the conventional method does not include a heating step before the washing step. In another aspect, this method reduces the operation time and throughput time compared to conventional methods. In another aspect, the conventional method does not include a heating step before the washing step. In another aspect, this method is suitable for automation and reduces complexity compared to conventional methods. In another aspect, the conventional method does not include a heating step before the washing step.

[0022] Another embodiment described herein is a plurality of target nucleic acid sequences isolated using the method described herein.

[0023] Another embodiment described herein is a means for isolating a plurality of target nucleic acid sequences, comprising any of the means, methods, steps, or compositions described herein.

[0024] Another embodiment described herein is the use of the method herein for isolating multiple target nucleic acid sequences.

[0025] A patent file or application file must include at least one color drawing. A copy of this patent or patent application publication, including the color drawing(s), will be provided by the government office upon request and payment of the required fees. [Brief explanation of the drawing]

[0026] [Figure 1] Figure 1 is a schematic diagram of the factors influencing hybridization of single-stranded DNA with a complementary partner (e.g., primer or probe). Kinetics are important in the composite system. Achieving on-target double stranding through hybridization is typically time-consuming. Using a thawing step after target capture simplifies the workflow while increasing specificity, improving yield, and reducing size bias. This system can be modified by increasing the temperature of the thawing step to increase GC-rich sequences. [Figure 2] Figure 2 shows a flowchart of a standard workflow for preparing a sequencing library using hybridization capture. [Figure 3] Figure 3 shows a schematic diagram of the workflow for preparing a sequencing library using a standard hybridization capture workflow, and describes the parameters at each step. [Figure 4]Figure 4 is a flowchart of a simplified “melt” hybridization capture workflow that simplifies the steps, reduces manual handling time and turnaround time, increases specificity, improves yield, and reduces size bias. [Figure 5] Figure 5 is a flowchart of a simplified “melt” hybridization capture workflow, including exemplary time and temperature at each step. [Figure 6] Figure 6 shows a schematic diagram of the workflow for preparing a sequencing library using a simplified “melting” hybridization capture workflow, with example parameters for each step. [Figure 7] Figures 7A and 7B compare the standard hybridization capture method (xGEN SOP) with the simplified "melt" hybridization (short Hyb) capture method using hybridization incubations of 24 hours, 30 minutes, or 15 minutes at 65°C. Figure 7A shows the on-target percentage, and Figure 7B shows the adjacent on-target percentage. The targeting panel used contained 18,815 targeting probes and was hybridized with a 250 ng capture input NA12878 gDNA library. Melt-simple binding at 30 minutes (e.g., short Hyb 30) was performed similarly to the standard overnight hybridization. The improvement in the melt-simple binding approach is most clearly observed in the 30-minute hybridization. [Figure 8]Figures 8A and 8B compare the overnight hybridization-capture method with and without the "thaw-simple" step. Figure 8A shows the percentage and mean of on-target with and without thawing, and Figure 8B shows the percentage and mean of adjacent on-targets with and without thawing. The targeting panel used here contained 18,815 targeting probes and was hybridized with a 250 ng capture input NA12878 gDNA library. The thawing process exhibits higher specificity than the process without thawing. [Figure 9] Figure 9 shows a comparison of on-target hybridization capture percentages for 2 hours and overnight under standard conditions (SOP +Form), standard conditions without formamide in the hybridization buffer (SOP -Form), and when a melt-simple binding step is included. [Figure 10] Figure 10 shows a comparison of HS library sizes for 2-hour and overnight hybridization captures under standard conditions (SOP +Form), standard conditions without formamide in the hybridization buffer (SOP -Form), and when a melt-simple binding step is included. [Figure 11] Figure 11 shows a comparison of adjacent on-target percentages of hybridization capture at 2 hours and overnight under standard conditions (SOP +Form), standard conditions without formamide in the hybridization buffer (SOP -Form), and with a melt-simple binding step. [Figure 12] Figure 12 shows a comparison of the average target coverage of 2-hour and overnight hybridization captures under standard conditions (SOP +Form), standard conditions without formamide in the hybridization buffer (SOP -Form), and when a melt-simple binding step is included. [Figure 13]Figure 13 shows a comparison of 70-30 ratios of hybridization capture over 2 hours and overnight under standard conditions (SOP +Form), standard conditions without formamide in the hybridization buffer (SOP -Form), and when a melt-simple bonding step is included. [Figure 14] Figure 14 shows a comparison of the standard hybridization capture method (xGEN) and the melt-simple (Hyb V2) method with representative metrics such as GC bias, sampling uniformity, sampling diversity, redundancy, coverage, targeting, and sample yield, after 2-hour and overnight hybridization incubations. The results are shown in Tables 4 to 8. [Modes for carrying out the invention]

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art. For example, any nomenclature used in relation to cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization, as well as the techniques described herein, are well known and commonly used in the art. In case of any conflict, the provisions of this edition, including the definitions, shall prevail. Representative compositions, methods, and materials are described herein, but equivalent materials and methods may be used in practice.

[0028] As used herein, the terms “amino acid,” “nucleotide,” “polynucleotide,” “vector,” “polypeptide,” and “protein” have their general meanings as understood by biochemists skilled in the art. Standard single-letter nucleotides (A, C, G, T, U) and standard single-letter amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y) are used herein.

[0029] As used herein, terms such as “include,” “including,” “contain,” “containing,” and “having” mean “comprising.” This disclosure also intends other embodiments, whether expressly described or not, of which embodiments or elements “comprising,” “consisting of,” and “consisting essentially of” are expressly described or not.

[0030] Where used herein, the terms “a,” “an,” “the,” and similar terms used in the context of this disclosure (particularly in the context of the claims) shall be construed to cover both singular and plural unless otherwise indicated herein or unless the context clearly contradicts this. Furthermore, unless otherwise specified, “a,” “an,” or “the” means “one or more.”

[0031] As used herein, the term "or" may be conjunctive or disjunctive.

[0032] As used herein, the term “substantially” means to almost or considerably extent, but not entirely.

[0033] As used herein, the terms “about” or “approximately” applied to one or more values ​​of interest mean a value that is similar to a specified reference value or within the tolerance range for a particular value determined by those skilled in the art, which depends in part on how the value is measured or determined, such as the limits of the measuring system. In one embodiment, the term “about” refers to any value that includes both integer and fractional components within a variation of up to ±10% of the value modified by the term “about.” Alternatively, “about” may mean within three or more standard deviations by convention in the art. Or, as with respect to biological systems or processes, the term “about” may mean within one order of magnitude of the value, within five times in some embodiments, and within two times in some embodiments. As used herein, the symbol “~” means “about” or “approximately.”

[0034] All ranges disclosed in this document include endpoints as discrete values ​​and all integers and fractions specified within the range. For example, the range 0.1 to 2.0 includes 0.1, 0.2, 0.3, 0.4...2.0. Where the endpoint is modified using the term "approximately", the specified range is expanded by a variation of up to ±10% of any value within the range or within 3 or more standard deviations, including the endpoint.

[0035] As used herein, the terms “room temperature,” “RT,” or “ambient temperature” refer to a temperature of approximately 20–27°C at standard atmospheric pressure; approximately 25°C ± 10%; or ~25°C. As used herein, the term “overnight” refers to a period of time from about 12 hours to about 20 hours. In one embodiment, overnight refers to a period of time from about 14 hours to about 18 hours. In another embodiment, overnight refers to a period of time from about 16 hours. In another embodiment, overnight refers to a period of time from the start of a hybridization incubation on one day to the end of a hybridization incubation on the following day.

[0036] As used herein, the term "hybridization" refers to the process of combining two complementary single-stranded nucleic acid molecules to form a single double-stranded hybrid molecule through base pairing.

[0037] As used herein, the term “melting” refers to the process of heating samples of on-target and off-target double-stranded nucleic acid molecules to a temperature high enough to specifically dissociate the off-target double-stranded nucleic acid molecules into two separate single-stranded nucleic acid molecules. As used herein, the term “additive” refers to one or more components added to the buffer described herein to promote hybridization and improve overall specificity.

[0038] As used herein, the terms “standard” or “conventional” refer to typical target-sequence hybridization capture methods. In one embodiment, the standard method is the xGEN target-sequence hybridization capture method (Integrated DNA Technologies, Coralville, IA).

[0039] As used herein, the term “targeted enrichment” with respect to nucleic acids refers to increasing the relative concentration of a particular nucleic acid species in a sample.

[0040] As used herein, the term “nucleic acid” may refer to DNA, RNA, dsDNA, dsRNA, ssDNA, ssRNA, or DNA / RNA complexes or sequence hybrids obtained from any source, including target and non-target sequences. For example, nucleic acid samples may be obtained from artificial sources, or by chemosynthesis, or from viruses, prokaryotic cells including microorganisms, or eukaryotic cells. Biological samples may be vertebrates, invertebrates, plants, microorganisms, viruses, mycoplasmas, fungi, or archaea, including or excluding humans.

[0041] Nucleic acid samples may include, but are not limited to, whole genome sequences, parts of genome sequences, chromosome sequences, mitochondrial sequences, PCR products, whole genome amplification products, or products of other amplification protocols, such as cDNA sequences, mRNA sequences, whole transcript sequences, exons, or introns. These examples are not intended to limit the types of samples applicable to the embodiments described herein.

[0042] This specification describes an improved hybridization capture method and composition for enriching a target nucleic acid sequence from a population of nucleic acids. The method comprises the steps of: combining a population of nucleic acids with a complementary probe set in solution; hybridizing or binding the complementary probe set to the target nucleic acid; selectively immobilizing the probe / target nucleic acid complex; and agglutinating the selectively immobilized probe / target nucleic acid complex at a temperature lower than T m The method includes the steps of: exposing the complex to a solution to dissolve undesirable non-target substances; and washing the complex to remove unbound non-target substances, thereby enriching the target nucleic acid.

[0043] One embodiment described herein is a method for hybridization capture. In one embodiment, an on-beads melting step is described. Instead of assuming that the probe-target binding of the hyb-capture reaches equilibrium and follows probe-target dissociation (melting) kinetics similar to existing hybridization-capture methods, the method disclosed herein is T m Dissociation / melting are directly used as important hybridization capture qualifiers. After incubation of the hybridization capture, the biotinylated probe is bound to the streptavidin beads at low temperature. The target-probe-bead complex is then subjected to aggregation or immediately below T mNonspecific and undesirable non-target substances are removed by heating or "melting". This is expected to occur relatively quickly, as it should follow simple dissociation kinetics. The method involves only "melting" the double strands and the diffusion of the free non-target into solution. A notable feature of the approach in this disclosure is that a "capture" step is performed before the "melting" step.

[0044] In one embodiment, the method simplifies the hybridization capture workflow by combining the melting and removal of off-target hybridization with probe-capture using immobilized streptavidin. During the melt incubation, the biotin-probe remains bound to the streptavidin beads, and probe-target capture continues. Furthermore, the method incorporates a melting step that replaces a lengthy manual capture step with a short room-temperature incubation accompanied by mixing in an orbital or rotary shaker.

[0045] Another embodiment described herein is a specific buffer composition optimized to enhance the specificity and stringency in the method described herein. The buffer composition contains T to the double-stranded target GC base content. m Includes buffers, salts, surfactants, and additives that reduce dependency and improve capture. Adding certain additives reduces the detection of all probe targets in the composite sample. m The results converge to a narrow range. In one embodiment, the optimal type and level of additives are determined with respect to the application and probe design of each hyb-capture, improving on-target and uniformity performance. In another embodiment, incubation at a predetermined range of low temperatures during the melting step increases the on-target to off-target ratio of the captured target nucleic acid. In yet another embodiment, a simplified workflow is achieved. m Further improve the dependency and reduce the bias of dsDNA content towards GC content, T m The effect of the converging additive is realized.

[0046] Another embodiment described herein is a hybridization capture system. This hybridization capture method is a Hyb-capture-thaw workflow. In the first step, a probe panel is brought into contact with a nucleic acid sample under conditions that promote hybridization. Optionally, the probe panel may include a capture portion, for example, biotinylation, but is not limited to this. The biotinylation probe is complementary to the target nucleic acid or the nucleic acid to be enriched. In the first step, the goal is to increase the yield of hybridization capture. Specificity of nucleic acid capture is secondary to yield. In the second step, the biotinylation probe is immobilized on streptavidin beads. Probes containing and not containing the hybridized target are immobilized. In the third step, thawing is performed to dissociate all nonspecific hybridization interactions. While not bound by theory, it is also expected that after thawing, rehybridization of the captured probe and target sequence occurs, further improving both yield and specificity. In the fourth step, a washing step is performed to further remove unhybridized and weakly hybridized non-target nucleic acids.

[0047] Another embodiment is a composition for improved hybridization capture. In one embodiment, a hybridization capture buffer is provided that improves hybridization capture efficiency. In another embodiment, T m Modified reagents may be added. In another embodiment, T to the double-stranded target GC base content. m The capture can be improved by adding additives that reduce dependency.

[0048] Another embodiment is a method for hybridization capture. In one step, hybridization with low stringency is provided. In another step, capture (immobilization) is carried out at a temperature sufficient to facilitate immobilization. In another step, melting is carried out at a high temperature to reduce off-target hybridization. In another step, washing is carried out to reduce off-target hybridization, and if necessary, this washing step may be without high-temperature washing.

[0049] One embodiment described herein comprises the steps of (a) preparing a sample of nucleic acid molecules comprising a plurality of target nucleic acid sequences and a plurality of off-target nucleic acid sequences; (b) hybridizing the sample to a panel of nucleic acid probes complementary to the plurality of target nucleic acid sequences under hybridization conditions to generate a probe / target complex; (c) selectively immobilizing the probe / target complex to form an immobilized probe / target complex; and (d) agglutinating the immobilized probe / target complex at a temperature below T, for a time sufficient to dissociate the off-target nucleic acid sequences. mA method for enriching a population of nucleic acid target sequences in a sample, comprising the steps of: (a) heating; and (b) washing the immobilized probe / target complex to remove non-hybridized nucleic acid sequences and off-target nucleic acid sequences from the hybridized multiple target nucleic acid sequences, thereby enriching the multiple target nucleic acid sequences in the sample. In one embodiment, the panel of nucleic acid probes complementary to the multiple target nucleic acid sequences further comprises a capture portion. In another embodiment, the capture portion is biotin. In another embodiment, the hybridization conditions are: (a) a salt selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) a chelating agent selected from one or more of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[Tris(hydroxymethyl) A buffer selected from one or more of the following: tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate);(d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) a hybridization buffer comprising one or more additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA). In another embodiment, the hybridization buffer contains formamide. In yet another embodiment, the hybridization buffer does not contain formamide.

[0050] In one embodiment, the hybridization conditions include an incubation time ranging from about 10 minutes to about 48 hours. In another embodiment, the hybridization conditions include an incubation time ranging from about 2 hours to overnight. In yet another embodiment, a 2-hour incubation time yields comparable specificity and yield compared to an overnight incubation time. In yet another embodiment, the hybridization conditions include an incubation temperature ranging from about 55°C to about 75°C. In yet another embodiment, the hybridization conditions include an incubation temperature ranging from about 60°C to about 70°C. In yet another embodiment, the hybridization conditions include an incubation time of about 2 hours and an incubation temperature of about 65°C.

[0051] In another embodiment, the probe / target complex is selectively immobilized using streptavidin beads. In one embodiment, the probe / target complex is selectively immobilized under conditions including an incubation time in the range of about 10 minutes to about 48 hours. In another embodiment, the probe / target complex is selectively immobilized under conditions including an incubation temperature in the range of 20°C to 40°C. In yet another embodiment, the probe / target complex is selectively immobilized under conditions including an incubation time of about 30 minutes and an incubation temperature of room temperature. In another embodiment, the step of heating the immobilized probe / target complex is a) a salt selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) a chelating agent selected from one or more of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[Tris( A buffer selected from one or more of the following: [Hydroxymethyl)methyl]glycine (Tricine); [Tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenate (Cacodylate);(d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) a fusion buffer comprising one or more additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA). ;

[0052] In another embodiment, the step of heating the immobilized probe / target complex includes an incubation time ranging from about 5 minutes to about 1 hour. In one embodiment, the step of heating the immobilized probe / target complex includes an incubation temperature ranging from about 50°C to about 70°C. In another embodiment, the step of heating the immobilized probe / target complex includes an incubation time of about 20 minutes and an incubation temperature of about 55°C. In another embodiment, the step of washing the immobilized probe / target complex comprises two different washing buffers, each washing buffer independently comprising: (a) a salt selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) a chelating agent selected from one or more of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid A buffer selected from one or more of the following: (Bicine); N-[Tris(hydroxymethyl)methyl]glycine (Tricine); [Tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate);(d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) an additive selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA).

[0053] In another embodiment, the step of washing the immobilized probe / target complex includes an incubation time of approximately 5 to 15 minutes and an incubation temperature of approximately 60°C. In one embodiment, this method improves specificity and increases yield compared to conventional methods. In another embodiment, the conventional method does not include a heating step before the washing step. In another embodiment, this method improves the on-target percentage compared to conventional methods. In another embodiment, the conventional method does not include a heating step before the washing step. In another embodiment, this method reduces operation time and throughput time compared to conventional methods. In another embodiment, the conventional method does not include a heating step before the washing step. In another embodiment, this method is suitable for automation and reduces complexity compared to conventional methods. In another embodiment, the conventional method does not include a heating step before the washing step.

[0054] Another embodiment described herein is a plurality of target nucleic acid sequences isolated using the method described herein.

[0055] Another embodiment described herein is a means for isolating a plurality of target nucleic acid sequences, comprising any of the means, methods, steps, or compositions described herein.

[0056] Another embodiment described herein is the use of the method herein for isolating multiple target nucleic acid sequences.

[0057] It will be apparent to those skilled in the art that appropriate modifications and adaptations to the compositions, formulations, methods, processes, apparatus, assemblies, and uses described herein can be made without departing from the scope of any of their embodiments or aspects. The compositions, apparatus, assemblies, and methods provided are illustrative and are not intended to limit the scope of any disclosed embodiments. All the various embodiments, aspects, and options disclosed herein can be combined in any variation or repetition. The scope of the compositions, formulations, methods, apparatus, assemblies, and processes described herein includes all actual or possible combinations of the embodiments, aspects, options, examples, and preferred ones described herein. Any component or step disclosed herein can be omitted, replaced, or included elsewhere herein. The ratio of the mass of any component of any of the compositions or formulations disclosed herein to the mass of other components in the formulation or the total mass of other components in the formulation is disclosed herein as if it were expressly disclosed. If the meaning of any term in any patent or publication incorporated by reference conflicts with the meaning of any term used in this disclosure, the meaning of the term or phrase in this disclosure shall prevail. All patents and publications cited herein are incorporated herein by reference with respect to their specific teachings.

[0058] The various embodiments and aspects of the present invention described herein are summarized by the following clauses: Clause 1. A method for enriching a population of nucleic acid target sequences in a sample, (a) the step of preparing a sample of nucleic acid molecules containing multiple target nucleic acid sequences and multiple off-target nucleic acid sequences; (b) A step of hybridizing the sample to a panel of nucleic acid probes complementary to multiple target nucleic acid sequences under hybridization conditions to generate a probe / target complex; (c) The step of selectively immobilizing the probe / target complex and forming the immobilized probe / target complex; (d) The immobilized probe / target complex is subjected to a temperature below T, sufficient time to dissociate the off-target nucleic acid sequence. m The steps include heating; (e) Wash the immobilized probe / target complex to remove non-hybridized nucleic acid sequences and off-target nucleic acid sequences from the hybridized multiple target nucleic acid sequences, thereby enriching the multiple target nucleic acid sequences in the sample. Methods that include...

[0059] Clause 2. The method of Clause 1, further comprising a capture portion of a panel of nucleic acid probes complementary to multiple target nucleic acid sequences.

[0060] Clause 3. The method of Clause 2, wherein the capture portion is biotin.

[0061] Clause 4. Hybridization conditions are, (a) Salts selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) A chelating agent selected from one or more of the following: ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) A buffer selected from one or more of the following: tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[tris(hydroxymethyl)methyl]glycine (Tricine); [tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate); (d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) Additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA). A method according to any one of the clauses 1 to 3, comprising a hybridization buffer containing one or more of the following.

[0062] Clause 5. The method according to any one of Clauses 1 to 4, wherein the hybridization buffer contains formamide.

[0063] Clause 6. The method according to any one of Clauses 1 to 4, wherein the hybridization buffer does not contain formamide.

[0064] Clause 7. Hybridization conditions include an incubation period ranging from approximately 10 minutes to approximately 48 hours, using any one of the methods described in Clauses 1 to 6.

[0065] Clause 8. Hybridization conditions include an incubation period ranging from approximately 2 hours to overnight, as specified in any one of Clauses 1 to 7.

[0066] Clause 9. A method according to any one of Clauses 1 to 8, which yields equivalent specificity and yield with a 2-hour incubation period compared to an overnight incubation period.

[0067] Clause 10. A method according to any one of Clauses 1 to 9, wherein the hybridization conditions include an incubation temperature in the range of approximately 55°C to approximately 75°C.

[0068] Clause 11. A method according to any one of Clauses 1 to 10, wherein the hybridization conditions include an incubation temperature in the range of approximately 60°C to approximately 70°C.

[0069] Clause 12. A hybridization method according to any one of Clauses 1 to 11, wherein the hybridization conditions include an incubation time of approximately 2 hours and an incubation temperature of approximately 65°C.

[0070] Clause 13. The method according to any one of Clauses 1 to 12, wherein the probe / target complex is selectively immobilized using streptavidin beads.

[0071] Clause 14. The method according to any one of Clauses 1 to 13, wherein the probe / target complex is selectively immobilized under conditions including an incubation time ranging from approximately 10 minutes to approximately 48 hours.

[0072] Clause 15. The method according to any one of Clauses 1 to 14, wherein the probe / target complex is selectively immobilized under conditions including an incubation temperature in the range of approximately 20°C to approximately 40°C.

[0073] Clause 16. The method according to any one of Clauses 1 to 15, wherein the probe / target complex is selectively immobilized under conditions including an incubation time of approximately 30 minutes and an incubation temperature of room temperature.

[0074] Clause 17. The step of heating the immobilized probe / target complex, (a) Salts selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) A chelating agent selected from one or more of the following: ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) A buffer selected from one or more of the following: tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[tris(hydroxymethyl)methyl]glycine (Tricine); [tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate); (d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) Additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA). A method according to any one of the clauses 1 to 16, comprising a melting buffer containing one or more of the following.

[0075] Clause 18. The method of any one of Clauses 1 to 17, wherein the step of heating the immobilized probe / target complex includes an incubation time ranging from approximately 5 minutes to approximately 1 hour.

[0076] Clause 19. The method of any one of Clauses 1 to 18, wherein the step of heating the immobilized probe / target complex includes an incubation temperature in the range of approximately 50°C to approximately 70°C.

[0077] Clause 20. The method of any one of Clauses 1 to 19, wherein the step of heating the immobilized probe / target complex includes an incubation time of approximately 20 minutes and an incubation temperature of approximately 55°C.

[0078] Clause 21. The step of washing the immobilized probe / target complex includes two different washing buffers, each washing buffer independently, (a) Salts selected from one or more of monovalent, divalent, sodium, ammonium, cesium, or manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) A chelating agent selected from one or more of the following: ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA); (c) A buffer selected from one or more of the following: tris(hydroxymethyl)aminomethane (Tris); 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine); N-[tris(hydroxymethyl)methyl]glycine (Tricine); [tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS); 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES); 2-(N-morpholino)ethanesulfonic acid (MES); or dimethylarsenic acid (Cacodylate); (d) A surfactant selected from one or more of the following: sodium dodecyl sulfate (SDS), polysorbate 20 (Tween® 20), octylphenol ethoxylate (Triton X-100), octylphenoxypolyethoxyethanol (IGEPAL®-CA 630), nonylphenoxypolyethoxyethanol (NP-40), or cetrimonium bromide (CTAB); or (e) Additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide (DMSO), polyethylene glycol 400-1,000,000, glycerol, magnesium, tetramethylammonium chloride (TMAC), tetraethylammonium chloride (TEAC), triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin (BSA). The method of any one of the provisions of Articles 1 to 20, including one or more of the following.

[0079] Clause 22. The method according to any one of Clauses 1 to 21, wherein the step of washing the immobilized probe / target complex includes an incubation time of approximately 5 to 15 minutes and an incubation temperature of approximately 60°C.

[0080] Clause 23. A method according to any one of Clauses 1 to 22, which improves specificity and increases yield compared to conventional methods.

[0081] Clause 24. A conventional method which does not include a heating step prior to the washing step, as described in any one of Clauses 1 to 23.

[0082] Clause 25. A method according to any one of Clauses 1-24 that improves the on-target percentage compared to conventional methods.

[0083] Clause 26. A conventional method which does not include a heating step prior to the washing step, as described in any one of Clauses 1 to 25.

[0084] Clause 27. A method according to any one of Clauses 1 to 26 that reduces operation time and throughput time compared to conventional methods.

[0085] Clause 28. A conventional method which does not include a heating step prior to the washing step, as described in any one of Clauses 1 to 27.

[0086] Clause 29. A method according to any one of Clauses 1 to 28 that is suitable for automation and reduces complexity compared to conventional methods.

[0087] Clause 30. A conventional method which does not include a heating step prior to the washing step, as described in any one of Clauses 1 to 29.

[0088] Clause 31. Multiple target nucleic acid sequences isolated using the method of any one of Clauses 1 to 30.

[0089] Clause 32. Means for isolating multiple target nucleic acid sequences, including the methods described in any one of Clauses 1 to 30.

[0090] Clause 33. Use of any one of the methods described in Clauses 1 to 30 for isolating multiple target nucleic acid sequences.

[0091] Cited literature Yin and Zhao, "Kinetics and Dynamics of DNA Hybridization," Acc. Chem. Res. 44(11): 1172-1181 (2011). Wang et al., "Direct and sensitive miRNA profiling from low-input total RNA," RNA 13(1): 151-159 (2007). Grenwedel and Hsu, "Salt effects on the denaturation of DNA," Biopolymers 7(4): 557-570 (1969). Melchior and Von Hippel, "Alteration of the Relative Stability of dA·dT and dG·dC Base Pairs in DNA," Proc. Nat. Acad. Sci. USA 70(2): 298-302 (1973). Grenwedel et al., "The effects of aqueous neutral-salt solutions on the melting temperatures of deoxyribonucleic acids," Biopolymers 10(1):47-68 (1971). Vaduevamurthy et al., "Betaine structure and the presence of hydroxyl groups alters the effects on DNA melting temperatures," Biopolymers91(1): 85-94 (2008). [Examples]

[0092] Example 1 This example demonstrates that the performance of hybridization capture is improved by adding a thawing step during probe / target complex immobilization. Using the target capture protocol from Integrated DNA Technologies, Inc. as an example, hybridization was performed for 2 hours or overnight, with hybridization incubation occurring at 65–70°C. Furthermore, the hybridization buffer was either formamide-containing (+Form) or formamide-free (-Form). The target capture panel used contained 18,815 biotinylated targeting probes and was hybridized with a 250 ng capture input NA12878 gDNA library. Four replications were performed at each hybridization temperature and condition. Following hybridization capture, the hybridized probe / target complexes were incubated with streptavidin beads or treated by a simple-to-bind and melting step (simple-to-bind at 65°C) according to the IDT method "xGen for hydridization capture of DNA libraries" 2020 (Integrated DNA Technologies, Coralville, IA; "SOP", such teachings are incorporated herein by reference).

[0093] As shown in Figure 9, adding a melting step after capture to streptavidin beads (melt-simple binding) increased the on-target percentage for both 2-hour and overnight hybridization incubations. Adding a melting step during immobilization increased the on-target percentage in 2-hour hybridization from 75% (SOP + Form) to 86%. For overnight hybridization reactions, adding a melting step to immobilization increased the on-target percentage from 85% (SOP + Form) to 87% (melt).

[0094] Figure 10 shows that adding a melting step during bead capture improves the HS library size for both 2-hour and overnight hybridization incubations. Adding a melting step during immobilization improves the HS library size to 2.13 × 10⁶ for a 2-hour hybridization incubation. 7 (SOP + Form) 3.63 × 10 7 (Melting) increased. Furthermore, by adding a melting step during immobilization, the HS_library_size increased to 4.88 × 10⁶ for an overnight incubation. 7 (SOP + Form) 5.88 × 10 7 (Melting) increased. By adding a melting step during immobilization, the HS_library_size for both SOP-Form conditions and melting conditions was similar for 2-hour and overnight hybridization incubations.

[0095] Figure 11 shows that adding a melting step during bead capture improves the percentage of adjacent on-target particles for both 2-hour and overnight hybridization incubations. Adding a melting step during immobilization increased the percentage of adjacent on-target particles for 2-hour hybridization from 81% (SOP + Form) and 65% (SOP - Form) to 92% (melted). Adding a melting step to immobilization for overnight hybridization incubation also improved the percentage of adjacent on-target particles for overnight hybridization from 92% (SOP + Form) and 79% (SOP - Form) to 93% (melted).

[0096] Figure 12 shows that adding a melting step during bead capture improves average target coverage for both 2-hour and overnight hybridization incubations. Adding a melting step during immobilization increased the average target coverage for 2-hour hybridization from 93.9 (SOP + Form) and 102 (SOP - Form) to 152 (melted). Furthermore, adding a melting step to immobilization improved the overnight hybridization incubation. The average target coverage for overnight hybridization incubation increased from 145 (SOP + Form) and 117 (SOP - Form) to 152 (melted).

[0097] Figure 13 shows the 70-30 ratio, a measure of GC skew in sequencer readings. The 70-30 ratio is often used to assess the potential for sequence bias in the library preparation process, but it also reflects the target sequence content. For the capture panel used in this example, the true unbiased ratio is expected to be 0.8-1.0. As shown, adding a melting step during immobilization improves the 70-30 ratio for both 2-hour and overnight hybridization incubations. Figure 13 shows that for 2-hour hybridization, the 70-30 ratio decreased from 1.83 (SOP + Form) and 1.14 (SOP - Form) to 0.0.911 (melted). Furthermore, for overnight hybridization incubation, the 70-30 ratio decreased from 1.38 (SOP + Form) and 1.18 (SOP - Form) to 0.929 (melted).

[0098] Example 2 The workflow for preparing a library for sequencing using a simplified hybridization target capture method (also known herein as melt-simple or Hyb V2) is shown in Figures 4–6. A comparison of the complexity of the standard workflow (shown in Figures 1–3) (e.g., xGEN hybridization capture, IDT) is illustrated in Table 1.

[0099] [Table 1]

[0100] Example 3 As shown in Tables 2 and 3, the melt-simple or Hyb V2 workflows were compared to the standard xGEN method using multiple probe panels.

[0101] [Table 2]

[0102] [Table 3]

[0103] Figure 14 shows a graph comparing the thaw-simple or Hyb V2 workflow with the standard xGEN. For equivalent hybridization times, thaw-simple or Hyb V2 performs better than xGEN and yields higher DNA after capture. Table 4 shows the comparison ratios.

[0104] [Table 4]

[0105] Tables 5-7 show general parameters comparing Hyb V2 and xGEN at various hybridization times (overnight vs. 2 hours). Table 8 compares xGEN at 2 hours with xGEN overnight.

[0106] [Table 5]

[0107] [Table 6]

[0108] [Table 7]

[0109] [Table 8]

[0110] These results indicate that the simplified Hyb V2 workflow does not negatively impact performance, and that Hyb V2 performs better with short hybridization targets.

[0111] Example 4 A simplified Hyb V2 workflow for hybridizing equivalently prepared Prism and Kapa libraries was compared to xGEN using IDP, AML, and Standard 500 probe sets. The results are shown in Tables 9–11.

[0112] [Table 9]

[0113] [Table 10]

[0114] [Table 11]

[0115] For 2-hour hybridization, the metrics for Prism libraries were improved using the Hyb V2 workflow. 2-hour hybridization using Hyb V2-Prism provided better overall metrics and comparable or better coverage compared to overnight hybridization using xGEN-Kapa. Furthermore, xGEN's hyb-capture is GC-biased for all panels tested. The Hyb V2 method mitigates the GC bias of the Prism library (for example, this method rescues AT content). This indicates that the Hyb V2 method is tunable in the "melting" step and can be used to modulate the GC bias.

Claims

1. A method for enriching a population of nucleic acid target sequences in a sample, (a) A step of preparing a sample of nucleic acid molecules containing multiple target nucleic acid sequences and multiple off-target nucleic acid sequences; (b) A step of hybridizing the sample to a panel of nucleic acid probes complementary to multiple target nucleic acid sequences under hybridization conditions to generate a probe / target complex; (c) Selectively immobilizing the probe / target complex to form the immobilized probe / target complex, and adding the fusion buffer; (d) The immobilized probe / target complex and thaw buffer for a sufficient amount of time to dissociate the off-target nucleic acid sequence. m The following steps involve heating to the following temperature: (e) Wash the immobilized probe / target complex to remove non-hybridized nucleic acid sequences and off-target nucleic acid sequences from the hybridized multiple target nucleic acid sequences, thereby enriching the multiple target nucleic acid sequences in the sample. Includes, Here, step (d) is performed before step (e), The aforementioned method.

2. The method according to claim 1, further comprising a capture portion in which a panel of nucleic acid probes complementary to multiple target nucleic acid sequences.

3. The method according to claim 2, wherein the capture portion is biotin.

4. Hybridization conditions are, (a) Salts selected from one or more of monovalent, divalent, sodium, ammonium, cesium, manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) A chelating agent selected from one or more of ethylenediaminetetraacetic acid, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid, or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; (c) A buffer selected from one or more of the following: tris(hydroxymethyl)aminomethane; 2-(bis(2-hydroxyethyl)amino)acetic acid); N-[tris(hydroxymethyl)methyl]glycine; [tris(hydroxymethyl)methylamino]propanesulfonic acid; 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid; 3-(N-morpholino)propanesulfonic acid; piperazine-N,N'-bis(2-ethanesulfonic acid); 2-(N-morpholino)ethanesulfonic acid; or dimethylarsenic acid; (d) A surfactant selected from one or more of sodium dodecyl sulfate, polysorbate 20, octylphenol ethoxylate, octylphenoxypolyethoxyethanol, nonylphenoxypolyethoxyethanol, or cetrimonium bromide; or (e) Additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide, polyethylene glycol 400 to 1,000,000, glycerol, magnesium, tetramethylammonium chloride, tetraethylammonium chloride, triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin; The method according to claim 1, comprising a hybridization buffer containing one or more of the following.

5. The method according to claim 4, wherein the hybridization buffer contains formamide.

6. The method according to claim 4, wherein the hybridization buffer does not contain formamide.

7. The method according to claim 1, wherein the hybridization conditions include an incubation time in the range of 10 minutes to 48 hours.

8. The method according to claim 1, wherein the hybridization conditions include an incubation period ranging from two hours to overnight.

9. The method according to claim 8, wherein equivalent specificity and yield can be obtained with an incubation time of 2 hours compared to an incubation time of 12 nights.

10. The method according to claim 1, wherein the hybridization conditions include an incubation temperature in the range of 55°C to 75°C.

11. The method according to claim 1, wherein the hybridization conditions include an incubation temperature in the range of 60°C to 70°C.

12. The method according to claim 1, wherein the hybridization conditions include an incubation time of 2 hours and an incubation temperature of 65°C.

13. The method according to claim 1, wherein the probe / target complex is selectively immobilized using streptavidin beads.

14. The method according to claim 1, wherein the probe / target complex is selectively immobilized under conditions including an incubation time ranging from 10 minutes to 48 hours.

15. The method according to claim 1, wherein the probe / target composite is selectively immobilized under conditions including an incubation temperature in the range of 20°C to 40°C.

16. The method according to claim 1, wherein the probe / target complex is selectively immobilized under conditions including an incubation time of 30 minutes and an incubation temperature of room temperature.

17. (a) Salts selected from one or more of monovalent, divalent, sodium, ammonium, cesium, manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) A chelating agent selected from one or more of ethylenediaminetetraacetic acid, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid, or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; (c) A buffer selected from one or more of the following: tris(hydroxymethyl)aminomethane; 2-(bis(2-hydroxyethyl)amino)acetic acid); N-[tris(hydroxymethyl)methyl]glycine; [tris(hydroxymethyl)methylamino]propanesulfonic acid; 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid; 3-(N-morpholino)propanesulfonic acid; piperazine-N,N'-bis(2-ethanesulfonic acid); 2-(N-morpholino)ethanesulfonic acid; or dimethylarsenic acid; (d) A surfactant selected from one or more of sodium dodecyl sulfate, polysorbate 20, octylphenol ethoxylate, octylphenoxypolyethoxyethanol, nonylphenoxypolyethoxyethanol, or cetrimonium bromide; or (e) Additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide, polyethylene glycol 400 to 1,000,000, glycerol, magnesium, tetramethylammonium chloride, tetraethylammonium chloride, triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin; The method according to claim 1, comprising a melting buffer containing one or more of the following.

18. The method according to claim 1, wherein the step of heating the immobilized probe / target composite includes an incubation time in the range of 5 minutes to 1 hour.

19. The method according to claim 1, wherein the step of heating the immobilized probe / target composite includes an incubation temperature in the range of 50°C to 70°C.

20. The method according to claim 1, wherein the step of heating the immobilized probe / target composite includes an incubation time of 20 minutes and an incubation temperature of 55°C.

21. The step of washing the immobilized probe / target complex includes two different washing buffers, each washing buffer being used independently. (a) Salts selected from one or more of monovalent, divalent, sodium, ammonium, cesium, manganese, chloride, citrate, sulfate, perchlorate, isothiocyanate, or guanidinium; (b) A chelating agent selected from one or more of ethylenediaminetetraacetic acid, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid, or 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; (c) A buffer selected from one or more of the following: tris(hydroxymethyl)aminomethane; 2-(bis(2-hydroxyethyl)amino)acetic acid); N-[tris(hydroxymethyl)methyl]glycine; [tris(hydroxymethyl)methylamino]propanesulfonic acid; 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 2-[[1,3-dihydroxy-2-(hydroxymethyl)propane-2-yl]amino]ethanesulfonic acid; 3-(N-morpholino)propanesulfonic acid; piperazine-N,N'-bis(2-ethanesulfonic acid); 2-(N-morpholino)ethanesulfonic acid; or dimethylarsenic acid; (d) A surfactant selected from one or more of sodium dodecyl sulfate, polysorbate 20, octylphenol ethoxylate, octylphenoxypolyethoxyethanol, nonylphenoxypolyethoxyethanol, or cetrimonium bromide; or (e) Additives selected from one or more of the following: glycine, betaine, glycine-betaine, 7-deaza-2'-deoxyguanosine, dimethyl sulfoxide, polyethylene glycol 400 to 1,000,000, glycerol, magnesium, tetramethylammonium chloride, tetraethylammonium chloride, triethylamine hydrochloride, ethylene carbonate, dextran sulfate, or bovine serum albumin; The method according to claim 1, comprising one or more of the above.

22. The method according to claim 1, wherein the step of washing the immobilized probe / target complex includes an incubation time of 5 to 15 minutes and an incubation temperature of 60°C.

23. The method according to claim 1, which improves specificity and increases yield compared to conventional target sequence hybridization capture methods.

24. The method according to claim 23, wherein the conventional target sequence hybridization capture method does not include a heating step before the washing step.

25. The method according to claim 1, which improves the on-target percentage compared to conventional target sequence hybridization capture methods.

26. The method according to claim 25, wherein the conventional target sequence hybridization capture method does not include a heating step before the washing step.

27. The method according to claim 1, which reduces operation time and throughput time compared to conventional target sequence hybridization capture methods.

28. The method according to claim 27, wherein the conventional target sequence hybridization capture method does not include a heating step before the washing step.

29. The method according to claim 1, which is suitable for automation and reduces complexity compared to conventional target sequence hybridization capture methods.

30. The method according to claim 29, wherein the conventional target sequence hybridization capture method does not include a heating step before the washing step.

31. Use of the method according to claim 1 for isolating multiple target nucleic acid sequences.

Citation Information

Patent Citations

  • Optimization of multiple gene analysis of tumor samples

    JP2014507133A

  • Tm-enhancing blocking oligonucleotides, as well as baits for improved target enrichment and reduced off-target selection.

    JP2015521853A

  • Target sequence enrichment

    JP2016515384A

  • Target sequence enrichment

    JP2017537657A

  • Microarray probe Tm matching by selective destabilization

    US20070087370A1